Biblioteca clínica

Modelos

Entra para guardar tu sesión o suscríbete para abrir la biblioteca completa. Puedes seguir gratis con fichas parciales.

¿Prefieres esperar? Déjame tu correo: te aviso cuando abra el acceso completo y tendrás precio de fundador.

TU MENTOR · ATLASAtlas de la psicoterapia
Vista
Lista Red de afinidades Mapamundi Genealogía
Home

Psychedelics · 2020

Psilocybin-Assisted Therapy (PAT)

Change is sought by preparing for, holding and integrating the psilocybin experience in order to favour a temporary loosening of emotional, perceptual and meaning-related patterns.

Psilocybin-Assisted Therapy (PAT) constitutes a contemporary family of combined interventions in which one or more administrations of psilocybin are embedded within a structured psychological frame. Its common architecture organises treatment into prior preparation, support during the acute experience and subsequent integration, and gives a central role to set — the person's expectations, history, emotional state, intentions and disposition — to setting — physical environment, music, safety and interpersonal conditions — and to an alliance of sufficient trust to get through intense states of consciousness without imposing a predetermined meaning on them. During administration, a warm, attentive and minimally directive therapeutic presence usually predominates, aimed at safety, attention to inner experience and approaching difficult emotions, sensations, memories or images; afterwards, integration turns the experience into a comprehensible narrative, identifies what has been learned and links it to concrete changes in everyday life. Psilocybin functions simultaneously as a pharmacological intervention and as a catalyst of a subjective experience whose effect depends on context, while the psychotherapeutic component may be supportive or may incorporate specific frameworks such as ACT, MBCT, CBT, motivational interviewing, existential therapy or others depending on the indication. The contemporary literature shows a broad convergence on the three-phase structure, but also considerable heterogeneity in therapeutic intensity, added techniques, facilitator training, manualisation and fidelity monitoring, so PAT is better understood as a family of clinical protocols under development than as a single, fully standardised psychotherapy. (Johnson, Richards & Griffiths, 2008; Guss et al., 2019; Sloshower et al., 2020; Kittur et al., 2025).

Theory of change

The person changes when an intensified psilocybin experience is passed through within a safe set and setting, is held without excessive avoidance, and is then integrated into new meanings, priorities and actions.

Core ideas

  1. Psilocybin and the psychological context form a combined intervention

    Contemporary practice administers psilocybin within a package that includes preparation, accompaniment and integration, so the clinical outcome cannot automatically be attributed to the drug in isolation. The subjective experience is modified by expectations, relationship, environment and added psychotherapeutic techniques, while the pharmacology itself temporarily alters the way those factors are processed. Current research has not yet sufficiently dismantled the independent contributions of each component. (Kittur et al., 2025, Mapping psilocybin therapy; Sloshower et al., 2020, Psilocybin-assisted therapy of major depressive disorder using ACT as a therapeutic frame).

  2. Set and setting are active components of the treatment

    The person's internal state, their expectations and fears, their trust in the therapists and the physical characteristics of the room all influence how a psychedelic experience is organised. Preparation of set and setting is therefore not treated as decoration or secondary logistics, but as an intervention that reduces risk, orients attention and enables the emerging material to be passed through within a frame of safety. (Johnson, Richards & Griffiths, 2008, Human hallucinogen research: Guidelines for safety; Porley Silva, 2022, Psilocibina en Psicoterapia).

  3. Preparation turns uncertainty into a capacity to get through the experience

    The preparatory sessions build trust, explain the range of possible effects, clarify boundaries and teach ways of responding to fear, disorientation or difficult emotional material. Their function is to enable the person to enter the psychedelic state with enough knowledge and safety to reduce avoidable panic reactions, without fixing expectations about what they should see, feel or understand. (Johnson, Richards & Griffiths, 2008, Human hallucinogen research: Guidelines for safety; Guss et al., 2019, Yale Manual for Psilocybin-Assisted Therapy of Depression).

  4. During the acute phase, presence predominates over interpretation

    Contemporary protocols converge on a stance of physical and psychological support, introspective orientation and low directiveness while psilocybin is exerting its maximum effects. The therapist's main task consists in sustaining safety, responding to needs and enabling the person to stay with the experience, reserving interpretation, formulation and more explicit psychotherapeutic techniques for preparation and integration. (Kittur et al., 2025, Mapping psilocybin therapy; Guss et al., 2019, Yale Manual for Psilocybin-Assisted Therapy of Depression).

  5. Approaching what is difficult can become a corrective experience

    A distinctive part of the psychedelic frame consists in preparing the person to approach intense emotions, images, memories and sensations instead of automatically escaping them. Interpersonal safety and the transience of the state allow a less avoidant relationship with distress to be rehearsed, and the ACT variants turn this experience into explicit learning about acceptance and psychological flexibility. (Johnson, Richards & Griffiths, 2008, Human hallucinogen research: Guidelines for safety; Sloshower et al., 2020, Psilocybin-assisted therapy of major depressive disorder using ACT as a therapeutic frame).

  6. Integration turns an extraordinary state into everyday change

    The intensity of a psychedelic experience does not in itself constitute a therapeutic transformation. Integration reconstructs what was lived, organises memory and emotion, examines meanings, distinguishes insight from certainty and seeks verifiable consequences in values, decisions and behaviour. Treatment gains continuity when what happened can be incorporated into the biography and into ordinary life without depending on reproducing the same state of consciousness. (Guss et al., 2019, Yale Manual for Psilocybin-Assisted Therapy of Depression; Kittur et al., 2025, Mapping psilocybin therapy).

  7. PAT admits different psychotherapeutic frameworks without losing its common architecture

    Current trials show that the preparation-administration-integration structure can house different psychotherapies depending on the indication: ACT, ACE or PCT in depression; CBT, MI or MET in addictions; existential or supportive-expressive approaches in serious medical illness; and emerging adaptations for OCD/BDD. The consistency lies in the clinical container, while the specific theory of suffering and the techniques of integration may change between protocols. (Kittur et al., 2025, Mapping psilocybin therapy; CAMH, 2023, Protocol 149/2021).

  8. ACT offers one of the most developed formulations of integration

    Yale's proposal for depression interprets the psilocybin experience as a possible source of direct contact with acceptance, the present, defusion, self-as-context, values and committed action. Preparation can predispose the person to recognise these processes, and integration uses concrete episodes from the session as experiential references for consolidating psychological flexibility. This formulation is influential and manualised, but it represents one variant of PAT and not its universal theory. (Sloshower et al., 2020, Psilocybin-assisted therapy of major depressive disorder using ACT as a therapeutic frame; Guss et al., 2019, Yale Manual for Psilocybin-Assisted Therapy of Depression).

  9. Psychological safety depends as much on selection as on the relationship

    The risks most characteristic of a psychedelic session include intense anxiety, panic, disorganisation or infrequent psychiatric reactions, and their prevention begins before administration. Medical and psychiatric screening, trust in the team, explanation of possible effects, a safe environment, continuous presence and subsequent follow-up form an integrated system of protection that cannot be replaced by a single crisis technique. (Johnson, Richards & Griffiths, 2008, Human hallucinogen research: Guidelines for safety; CAMH, 2023, Protocol 149/2021).

  10. The experience of the self can be loosened without imposing a metaphysical interpretation

    Psilocybin can intensely alter self-perception and produce experiences of unity, transcendence or a temporary diminution of habitual identity. Clinically, these phenomena can be used to question fusion with rigid narratives and to widen perspectives, provided that their meaning is constructed with the person and that the therapist does not turn a subjective experience into a spiritual, ontological or diagnostic truth. (Sloshower et al., 2020, Psilocybin-assisted therapy of major depressive disorder using ACT as a therapeutic frame; Johnson, Richards & Griffiths, 2008, Human hallucinogen research: Guidelines for safety).

Influences

  • Tradition of psychedelic psychotherapy
  • Set and setting
  • Supportive psychotherapy
  • Acceptance and Commitment Therapy (ACT)
  • Mindfulness-Based Cognitive Therapy (MBCT)
  • Cognitive behavioural therapy (CBT)
  • Motivational Interviewing (MI)
  • Motivational Enhancement Therapy (MET)
  • Existential psychotherapy
  • Supportive-expressive psychotherapy

Key references

  • Johnson, M. W., Richards, W. A., & Griffiths, R. R. (2008). Human hallucinogen research: Guidelines for safety. Journal of Psychopharmacology, 22(6), 603-620. https://doi.org/10.1177/0269881108093587.
  • Guss, J., Sloshower, J., Krause, R., & Wallace, R. (2019). Yale Manual for Psilocybin-Assisted Therapy of Depression (Version 4.2, revised August 2019). Yale University.
  • Sloshower, J., Guss, J., Krause, R., Wallace, R. M., Williams, M. T., Reed, S., & Skinta, M. D. (2020). Psilocybin-assisted therapy of major depressive disorder using Acceptance and Commitment Therapy as a therapeutic frame. Journal of Contextual Behavioral Science, 15, 59-67. https://doi.org/10.1016/j.jcbs.2019.11.002.
  • Centre for Addiction and Mental Health (CAMH). (2023). Evaluating the feasibility, clinical effects, and safety of psilocybin-assisted psychotherapy for treatment-resistant obsessive-compulsive disorder: An open-label clinical trial. Protocol 149/2021, Version 1.0, 20 October 2023.
  • Porley Silva, J. (2022). Psilocibina en Psicoterapia: Antecedentes, Actualidad y Oportunidades. Trabajo final de grado, Facultad de Psicología, Universidad de la República, Montevideo, Uruguay.
  • Kittur, M. E., Burgos M., L. A., Jones, B. D. M., Blumberger, D. M., Mulsant, B. H., Rosenblat, J. D., & Husain, M. I. (2025). Mapping psilocybin therapy: A systematic review of therapeutic frameworks, adaptations, and standardization across contemporary clinical trials. Journal of Affective Disorders, article 119952. https://doi.org/10.1016/j.jad.2025.119952.